Quizartinib is a potent and selective FLT3 tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring FLT3-ITD mutations.… Read more




Quizartinib is a potent and selective FLT3 tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring FLT3-ITD mutations. To support stringent quality control and regulatory compliance, this category provides a comprehensive selection of Quizartinib reference standards, including the active pharmaceutical ingredient, identified process-related impurities, and degradation products. These materials are essential for impurity profiling and rigorous analytical testing throughout the drug development lifecycle. Additionally, stable isotope labelled compounds, such as deuterium-labelled Quizartinib and its metabolites, are available to serve as high-quality internal standards in mass spectrometry-based assays, ensuring accurate quantification and reliable method validation. These analytical tools enable laboratories to maintain the highest precision when characterizing Quizartinib and assessing the safety and efficacy of its formulations.